| Date | Filer | Title | Filing | Type | Shares Traded | Price | Total Held |
|---|---|---|---|---|---|---|---|
| Aug 21, 2018 |
Director
Trans History: 18
|
Director | Form 4 | Open market or private purchase of non-derivative or derivative security | 3,894 | $6.47 | 3,894 |
| Aug 21, 2018 |
Director
Trans History: 18
|
Director | Form 4 | Open market or private purchase of non-derivative or derivative security | 3,894 | $6.47 | 3,894 |
| Aug 23, 2018 |
Ten Percent Owner
Trans History: 18
|
Ten Percent Owner | Form 4 | Conversion of derivative security | 4,386 | -- | 4,386 |
| Apr 23, 2021 |
Chief Medical Officer
Trans History: 12
|
Chief Medical Officer | Form 3/A | Amendment to an Initial Statement of Beneficial Ownership of Securities | 5,000 | -- | -- |
| Aug 23, 2018 |
Chief Scientific Officer
Trans History: 21
|
Chief Scientific Officer | Form 4 | Conversion of derivative security | 5,941 | -- | 7,354 |
| Jan 18, 2019 |
Chief Operating Officer
Trans History: 19
|
Chief Operating Officer | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 6,000 | $1.30 | 6,815 |
| Jan 18, 2019 |
Chief Operating Officer
Trans History: 19
|
Chief Operating Officer | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 6,000 | -- | 28,219 |
| Jun 10, 2021 |
Director
Trans History: 18
|
Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 7,528 | -- | 7,528 |
| Jun 10, 2021 |
Director
Trans History: 11
|
Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 7,528 | -- | 7,528 |
| Jun 10, 2021 |
Director
Trans History: 11
|
Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 7,528 | -- | 7,528 |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.